On March 29, 2022 Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, reported that new data were published in the peer-reviewed journal, Diagnostics (Basel), in an article titled, "Analytic and Clinical Validation of a Pan-Cancer NGS Liquid Biopsy Test for the Detection of Copy Number Amplifications, Fusions and Exon Skipping Variants (Press release, Biodesix, MAR 29, 2022, View Source [SID1234611085])." This peer-reviewed publication further validates the GeneStrat NGS test and the use of multiple classes of tumor markers in circulating free nucleic acid analysis as a surrogate for tumor tissue biopsies. [i]
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"These data extend on Biodesix’ testing of plasma for somatic nucleotide variants and indels in circulating nucleic acids by detecting amplifications, fusions and exon skipping. We can broadly assay for the major variant classes which includes actionable mutations in support of comprehensive molecular testing in lung cancer," said Gary Pestano, Ph.D., Chief Development Officer, Biodesix.
Additionally, Biodesix will present data associated with the GeneStrat ddPCR and NGS blood tests in a poster presentation focused on reporting validation studies of key actionable mutations in NSCLC entitled: Analytic and clinical validation of a new pan-cancer NGS liquid biopsy test for the detection of copy number variations, fusions/exon skipping, somatic variants and indels (Abstract number 5323), at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting from April 8-13, 2022. The full abstract can be found on the official AACR (Free AACR Whitepaper) website here. Poster presentations will be viewable after April 8th, 2022.
The company believes that the coupling of highly sensitive, rapid stand-alone droplet digital PCR (ddPCR) and the NGS techniques offers more comprehensive blood-based testing support for patients with non-small cell lung cancer (NSCLC) and provides clinically relevant information both before and after targeted treatment of patients with cancer.